Norditropin FlexPro / Norditropin NordiFlex
Submitted by Anonymous (not verified) on 11 February 2026 - 9:45
Norditropin FlexPro / Norditropin NordiFlex
ICH M15 guideline on general principles for model-informed drug development - Scientific guideline
Submitted by Anonymous (not verified) on 11 February 2026 - 8:12
ICH M15 guideline on general principles for model-informed drug development - Scientific guideline
ICH M15 Guideline on general principles for model-informed drug development - Step 5
Submitted by Anonymous (not verified) on 11 February 2026 - 8:10
ICH M15 Guideline on general principles for model-informed drug development - Step 5
Aliskiren product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 10 February 2026 - 14:45
Aliskiren product-specific bioequivalence guidance
PhV non-compliance notification contact points at National Competent Authority (NCA) level
Submitted by Anonymous (not verified) on 10 February 2026 - 14:20
PhV non-compliance notification contact points at National Competent Authority (NCA) level
Agenda of the CVMP meeting 10-12 February 2026
Submitted by Anonymous (not verified) on 10 February 2026 - 13:50
Agenda of the CVMP meeting 10-12 February 2026
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Date of authorisation: 17/10/2025, Status: Authorised
Submitted by Anonymous (not verified) on 10 February 2026 - 13:36
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Date of authorisation: 17/10/2025, Status: Authorised
Annex to 16-19 June 2025 CHMP Minutes
Submitted by Anonymous (not verified) on 10 February 2026 - 13:20
Annex to 16-19 June 2025 CHMP Minutes
Minutes of the CHMP meeting 16-19 June 2025
Submitted by Anonymous (not verified) on 10 February 2026 - 13:19
Minutes of the CHMP meeting 16-19 June 2025
Article 57 product data
Submitted by Anonymous (not verified) on 10 February 2026 - 12:30
Article 57 product data